WiseGuy Report’s latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma – Pipeline Review, H2 2016, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.
Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).
WiseGuy Report’s Pharmaceutical and Healthcare latest pipeline guide Pheochromocytoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Pheochromocytoma.
Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from WiseGuy Report’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Content:
Pheochromocytoma Overview 6
Therapeutics Development 7
Pipeline Products for Pheochromocytoma – Overview 7
Pipeline Products for Pheochromocytoma – Comparative Analysis 8
Pheochromocytoma – Therapeutics under Development by Companies 9
Pheochromocytoma – Therapeutics under Investigation by Universities/Institutes 10
Pheochromocytoma – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Pheochromocytoma – Products under Development by Companies 13
Pheochromocytoma – Products under Investigation by Universities/Institutes 14
Pheochromocytoma – Companies Involved in Therapeutics Development 15
Exelixis, Inc. 15
MediaPharma s.r.l. 16
Pfizer Inc. 17
Progenics Pharmaceuticals, Inc. 18
Valeant Pharmaceuticals International, Inc. 19
Pheochromocytoma – Therapeutics Assessment 20 Continued…..
For more information or any query mail at email@example.com
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
WISE GUY RESEARCH CONSULTANTS PVT LTD
75 Arlington Street, Suite 500,
Boston, Massaachusetts – 02116
United States of America
+1 646 845 9349 / +44 208 133 9349